ONCONOME TO USE PROTEOSHOP® FOR CANCER BIOMARKERS

18th April 2007

Proteome Sciences plc (“Proteome”) is pleased to announce that it is to apply its ProteoSHOP® proteomics toolbox to analyse prostate and colon cancer materials provided by Seattle based Onconome Inc. (“Onconome”).

Proteome has a strong track-record in the discovery and validation of cancer biomarkers and will apply its 2-dimensional gel western blotting technology to further characterise diagnostic antibodies developed by Onconome for the diagnosis and prognostic monitoring of patients with prostate and colon cancers. In addition Proteome will perform new biomarker discovery using Onconome’s materials on its high-throughput 2-dimensional gel electrophoresis platform and using its patented isobaric Tandem Mass Tags® for gel-free analyses.

Under the terms of the collaboration Proteome will receive research funding for the provision of ProteoSHOP® services.

Commenting on the collaboration H. Raymond Cairncross, Co-Founder and Chief Executive Officer of Onconome Inc. said:

“As a company dedicated to the discovery, development and commercialization of protein biomarkers for the early detection of prostate, colon and other types of cancers and life-threatening diseases, it is critical that we collaborate with companies highly skilled and experienced in the proteomics field. We feel we have found such a partner in Proteome Sciences and look forward to a mutually productive and profitable relationship.”

Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:

“We are pleased to announce this ProteoSHOP® deal building on the technological and commercial progress made in the last 12 months. Our unique combination of proteomics solutions for biomarker discovery and validation, linked to our considerable experience in oncology provides Onconome with access to the tools needed for further characterisation of their prostate and colon cancer biomarkers.

This collaboration reflects a growing need within the diagnostics and pharmaceutical industries for external sourcing of well characterised and validated protein biomarkers which ProteoSHOP® was designed to support. With a portfolio of well characterised biomarkers across a range of diseases and the patented technologies within ProteoSHOP® we are ideally placed to become the partner of choice for protein biomarker discovery projects.”